1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : PHARMACEUTICALS
  4. CAPLIN POINT LABORATORIES LTD.
Caplin Point Laboratories Ltd.
NSE: CAPLIPOINT | BSE: 524742

Caplin Point Labs Live Share Price Today, Share Analysis and Chart

Mid-range Performer
BasketIn 3 Starfolio Baskets
aboutCaplin Point Laboratories Ltd. (Caplin Point) is an Indian pharmaceutical company with a 100% export-oriented business model. Established in 1990, the company has evolved from a manufacturer of ointments and creams to a fully integrated pharmaceutica... Read More
Ask AI about Caplin Point Labs
2325.60-50.50(-2.13%)

55.01% Gain from 52W Low

134.0K
NSE+BSE Volume

NSE 30 Oct, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Loading...
- / 100
- / 100
57.9 / 100
Mid-range PerformerThese stocks have strong quality. Their reasonable financials and technicals make them potentially attractive to investorsView SimilarEmbed DVM
Analyst Price Target
-

15

S

10

W

0

O

2

T

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

High rank

12Positive11Negative

Pass in checklist52.2%

045
55
100

PE Valuation Check

Right Now
Overvalued
-6.4%
1 Year Forward
Fairly Valued
2.3%
INSIGHTCaplin Point Labs is overvalued at current PE, but fairly valued on future earnings estimates

Caplin Point Labs Stock Price Analysis

Day Price Range

-2.1% 1 Day return
2325.6 (LTP)
2,3102,422.4
LowHigh

Week Price Range

4.7% 1 Week return
2325.6 (LTP)
2,208.92,422.4
LowHigh

Month Price Range

-14.4% 1 Month return
2325.6 (LTP)
2,176.22,719.9
LowHigh

52 Week Price Range

14.4% 1 Year return
2325.6 (LTP)
1,500.32,990
LowHigh
View full Price History/Seasonality

Caplin Point Labs Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Hit

Caplin Point Labs's Revenue was higher than average estimate 2 times in past 3 years

EPS forecast

CURRENT EPS
84.1
AVG. ESTIMATE
95.6
LOW ESTIMATE
94.2
HIGH ESTIMATE
97
CURRENT EPS
AVG. ESTIMATE
Hit

EPS is expected to grow by 13.7% in FY27

Consensus Recommendation

2 ANALYST Recommendations
STRONG BUY

The consensus recommendation from 2 analysts for Caplin Point Labs is STRONG BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get
Upgrade Now

Caplin Point Labs Technical Analysis

Caplin Point Labs EMA & SMA

Bearish-6
1 bullish, 7 bearish
Bullish1
Bearish7
5 Day2332.7
10 Day2337.2
12 Day2347.8
20 Day2399.7
26 Day2432.6
50 Day2490.8
100 Day2442.5
200 Day2297.1

Caplin Point Labs Delivery And Volume

Daily Avg. Delivery Volume %
30 Oct, 202648.4%
Week46.3%
Month43.8%
Legend
Positive IndicatorNeutral IndicatorNegative Indicator

Caplin Point Labs Resistance and Support

2352.67
Pivot
First Resistance2395.3
Second Resistance2465.1
Third Resistance2507.7
First Support2282.9
Second Support2240.3
Third Support2170.5
Day RSI40.1
Day MACD-84.8
Day MFI24.3
Day MACD Signal Line-92.8

Caplin Point Labs Beta

1 Month0.5
1 Year0.8
3 Month0.4
3 Year1.0

Caplin Point Labs Price Change Analysis

↓-14.4%
Over 1 Month
LowHigh
2176.22719.9
↓-7.6%
Over 3 Months
LowHigh
2176.22990
↑36.1%
Over 6 Months
LowHigh
1710.52990
↑14.4%
Over 1 Year
LowHigh
1500.32990
All Technicals →

Caplin Point Labs Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026
 
NameCategorySharesShares %
P VijayalakshmiPromoter18,778,79024.7 %
Investor Education And Protection Fund Authority Ministry Of Corporate AffairsPublic2,134,6522.8 %
Uti Nifty 500 Index FundDii1,046,3741.4 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

All Shareholding details

Caplin Point Labs Deals - Insider, Bulk, Block and SAST

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
GRAVITON RESEARCH CAPITAL LLPBulkSell26 Aug 20241901.28396,355NSE
GRAVITON RESEARCH CAPITAL LLPBulkPurchase26 Aug 20241899.60396,355NSE
GRAVITON RESEARCH CAPITAL LLPBulkSell19 Aug 20241763.58444,478NSE
GRAVITON RESEARCH CAPITAL LLPBulkPurchase19 Aug 20241761.72444,478NSE
GRAVITON RESEARCH CAPITAL LLPBulkSell09 Sep 2021908.54381,306NSE
GRAVITON RESEARCH CAPITAL LLPBulkPurchase09 Sep 2021908.19381,306NSE
GRAVITON RESEARCH CAPITAL LLPBulkSell27 Jul 2021957.37414,981NSE
GRAVITON RESEARCH CAPITAL LLPBulkPurchase27 Jul 2021957.62414,981NSE
XTX MARKETS LLPBulkSell26 Jul 2021910.58460,816NSE
XTX MARKETS LLPBulkPurchase26 Jul 2021908.91464,203NSE
All deals
All insider trades

Caplin Point Labs Corporate Actions

Caplin Point Labs Dividend history and yield

Caplin Point Labs dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Caplin Point Labs dividend yield over time.

#Ex-Date
Dividend AmountDividend TypeRecord DateInstrument Type
118 Sep 2026
4FINAL18 Sep 2026Equity Share
229 May 2026
4INTERIM30 May 2026Equity Share
312 Sep 2025
3FINAL12 Sep 2025Equity Share
430 May 2025
3INTERIM30 May 2025Equity Share
523 Sep 2024
2.5FINAL-Equity Share

Caplin Point Labs Board Meetings

Caplin Point Labs past and upcoming board meetings.

#Ex-Date
PurposeNotes
112 Aug 2026
Quarterly Results & Final Dividend-
214 May 2026
Audited Results & Interim Dividend-
305 Feb 2026
Quarterly Results-
405 Nov 2025
Quarterly Results-
507 Aug 2025
Quarterly Results, Final Dividend & A.G.M.-

Caplin Point Labs Stock Split

Caplin Point Labs stock split details, including announcement, record, and ex-split dates, along with the split ratios

#Ex-Date
Old FVNew FVRecord Date
119 Oct 2016
10220 Oct 2016
All Corporate Actions

Caplin Point Labs Research Reports

Caplin Point Labs research reports with share price targets, and buy/hold/sell recommendations from top brokers.

#
Date
Broker NameTargetPrice When RecommendedTypeUpsideChange Since RecommendationLinks
114 May 2026ICICI Direct
Target
23201998.8Buy16.07%16.35%pdf
205 Feb 2026ICICI Direct21551825.7Buy18.04%27.38%pdf
309 Nov 2025ICICI Direct22951943.2Buy18.1%19.68%pdf
413 Aug 2025FundsIndia24992135.2Buy17.04%8.92%pdf
510 Nov 2024ICICI Direct
Target
24002012.2Buy19.27%15.57%pdf
All Reports of Caplin

Caplin Point Labs Corporate Filings

Caplin Point Labs BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

DateAnnouncement TitleDetailsLinks
07 Oct 2026
Caplin Point Laboratories Ltd - 524742 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulation, 2018 for the quarter and half year ended September 30, 2026.
PDF
28 Sep 2026
Caplin Point Laboratories Ltd - 524742 - Closure of Trading Window
Intimation of Closure of Trading Window for the quarter and half year ended September 30, 2026 commencing from October 01, 2026.
PDF
25 Sep 2026
Caplin Point Laboratories Ltd - 524742 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Voting Results and Scrutinizer Report for the 35th Annual General Meeting
PDF
25 Sep 2026
Caplin Point Laboratories Ltd - 524742 - Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceedings of 35th Annual General Meeting of the Company
PDF
25 Sep 2026
Caplin Point Laboratories Ltd - 524742 - Clarification With Respect To Volume Movement
Clarification with respect to Volume Movement
PDF
VIEW ALL

Caplin Point Labs DocumentsAsk MarketMind AI

Caplin Point Labs Earnings Call

Caplin Point Labs earnings calls, including management commentary and AI-generated summaries.

DateTitleLinks
19 Aug 2026Caplin Point Laboratories Ltd - 524742 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
12 Aug 2026Caplin Point Laboratories Ltd - 524742 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeLink
12 Aug 2026Caplin Point Laboratories Results Earnings Call for Q1FY27AudioVideo
21 May 2026Caplin Point Laboratories Ltd - 524742 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
14 May 2026Caplin Point Laboratories Results Earnings Call for Q4FY26 & Full YearAudioVideo
view all

Caplin Point Labs Annual Reports

Caplin Point Labs financials, including annual results, balance sheets, and cash flow statements.

DateReport TitleLinks
2026Annual Report Mar-2026Link
2025Annual Report Mar-2025Link
2024Annual Report Mar-2024Link
2023Annual Report Mar-2023Link
2022Annual Report Mar-2022Link

Caplin Point Labs Investor Presentations

Caplin Point Labs investor presentations, including business updates, financial insights, and strategic initiatives.

DateReport TitleLinks
12 Aug 2026Caplin Point Laboratories Ltd - 524742 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
05 Feb 2026Caplin Point Laboratories Ltd - 524742 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
09 Nov 2023CAPLIN POINT LABORATORIES LTD. - 524742 - September 30, 2023Link
09 Nov 2023CAPLIN POINT LABORATORIES LTD. - 524742 - Board Meeting Outcome for Financial Results For QE 30-09-2023Link
30 Oct 2021CAPLIN POINT LABORATORIES LTD. - 524742 - Announcement under Regulation 30 (LODR)-Investor PresentationLink

Caplin Point Labs - Company Profile

Caplin Point Labs Management Structure

Caplin Point Labs management structure with salaries, total experience, and qualifications.

NAMEDESIGNATIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Mr. Neelakandan KPresident(API R&D)99Mar 26
D. MuralidharanWhole Time Director,Chief Financial Officer60Mar 26
VENKATRAM GANAPATHYSUBRAMANIANGeneral Counsel,Company Secretary,Compliance Officer51Mar 26
Mr. Sivakumar BalasubramanianPlant Head49Mar 26
Dr. Vinayak Dinkar KadamAssociate Vice President(FR&D)47Mar 26
Yewale Bhushan RavindraGeneral Manager(Strategic Sourcing)37Mar 26
Mr. Umapathy VGeneral Manager34Mar 26
Raghavan CSenior General Manager31Mar 26
Dinesh RSenior General Manager30Mar 26

Caplin Point Labs Board of Directors

Caplin Point Labs Board of directors with salaries, total experience, and qualifications.

NAMEPOSITIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Sridhar GanesanNon Independent Executive Director / MD57Mar 25
VENKATRAM GANAPATHYSUBRAMANIANCo. Sec. / Comp. Officer / General Counsel54Mar 25
Deenadayalan SingaramIndependent Non Exe. Director5.5Mar 25
C K GariyaliIndependent Non Exe. Director3Mar 25
R NagendranIndependent Non Exe. Director2.25Mar 25
R VijayaraghavanIndependent Non Exe. Director1.5Mar 25
C C PaarthipanChairman & Non Executive Dir.-Mar 25
K C JohnAdditional Director-Mar 25
PARTHEEBAN VIVEK SIDDARTHVice Chairman & Additional Dir-Mar 25
ASHOK GORKEY PARTHEEBANVice Chairman & Additional Dir-Mar 25
D. MuralidharanWhole Time Director-Mar 25
Website: www.caplinpoint.net

About the company - Business Profile

Caplin Point Laboratories Ltd. (Caplin Point) is an Indian pharmaceutical company with a 100% export-oriented business model. Established in 1990, the company has evolved from a manufacturer of ointments and creams to a fully integrated pharmaceutical entity with a dominant presence in Latin America and Francophone Africa. It is expanding its footprint in regulated markets such as the USA, Canada, Australia, Mexico, and Brazil. The company operates through a unique business model that combines owning distribution networks with a focus on the "Bottom of the Pyramid" market segment in its core geographies.

Key Points

Key Facts

  • Founded Year: 1990
  • Headquarters: Chennai, Tamil Nadu
  • Stock Listing: BSE (524742) and NSE (CAPLIPOINT)
  • Business Model: Fully integrated, 100% export-oriented, owning end-to-end distribution networks in emerging markets.

Operations and Resources

  • Manufacturing Facilities: The company operates six manufacturing units located across Puducherry, Tamil Nadu (Gummidipoondi, Kakkalur), and Andhra Pradesh (Visakhapatnam).
  • R&D Infrastructure: Includes specialized units such as Amaris Clinical (CRO in Chengalpattu), OTICEL Bio-Park (Chennai) for bioequivalent dosage forms, and dedicated facilities for APIs and intermediates in Hyderabad and Chennai.
  • Assets: Maintains a robust cash reserve of ₹916 crore (as of FY24) and is debt-free.

Market Significance and Revenue

  • Core Markets: Latin America (primary revenue driver) and Francophone Africa.
  • Regulated Markets: Growing presence in the USA through its subsidiary, Caplin Steriles USA Inc., which serves as the front-end trading arm.
  • Segment Performance (H1 FY26):
    • Revenue from Operations: ₹1,044 crore (10.8% YoY growth).
    • EBITDA: ₹420 crore (18.1% YoY growth) with a margin of 38.3%.
    • PAT: ₹311 crore (21.6% YoY growth) with a margin of 28.3%.
  • Geographic Expansion: Recent entries and planned launches in Chile, Mexico, and Brazil (expected FY26-27).

Product Portfolio and Technology

  • Diverse Range: Over 5,000 product licenses and 650+ pharmaceutical formulations across 36 therapeutic segments.
  • Key Categories: Tablets, capsules, liquid and lyophilized injectables, prefilled syringes (PFS), ophthalmics, softgel capsules, and dermo-cosmetics.
  • Innovation Focus: Transitioning toward complex generic spaces, including specialty niche products, oncology (OSD and injectables), and inhalers.

Strategic Initiatives and Future Outlook

  • Capex Program: Allocated ₹1,000+ crore for investment projects, funded entirely through internal accruals.
  • Backward Integration: Focus on establishing own API facilities, including a general API plant in Visakhapatnam and an Oncology API facility in Chennai (expected Q1 FY27).
  • New Capacity: An OSD facility in Puducherry and a new injectable facility under Caplin One Labs are slated for completion in Q3 and Q4 of FY27, respectively.
  • Subsidiaries: Key units include Caplin Steriles Ltd (injectables for regulated markets), Caplin One Labs Ltd (Oncology), and several distribution subsidiaries across Central and South America.

Sustainability and Efficiency

  • Financial Metrics: Maintains a cash-surplus position with a cash conversion cycle of 117 days for receivables in H1 FY26.
  • Vertical Integration: Aims to achieve backward integration for a majority of its products to secure the supply chain and improve margins.

References

  1. Annual Report May 2025
  2. Investor Presentation Feb 2026
  3. Result Nov 2025
  4. Annual Report May 2024

Caplin Point Labs FAQ

Caplin Point Labs today is trading in the red, down by 2.13% at ₹2,325.6.
Caplin Point Labs is currently trading down 2.13% on an intraday basis. In the past week the stock rose 4.66%. Stock has been down 7.6% in the past quarter and rose 14.4% in the past year. You can view this in the share price history/seasonality section.
Caplin Point Labs is listed on NSE with the ticker CAPLIPOINT and on BSE as 524742. It's currently trading on NSE at a share price of ₹2,325.6 and on BSE with a share price of ₹2,336.4.
The market cap of Caplin Point Labs is ₹17,677.28 Cr. as of Oct 30, 2026.
Caplin Point Labs announced a FINAL dividend of 200% which equals ₹4 in Sep 18, 2026.The last three ex-dates for Caplin Point Labs were May 29, 2026, Sep 12, 2025 and May 30, 2025. To view the full dividend history of Caplin Point Labs click here.
Caplin Point Labs has never issued bonus shares, but it has issued 1 stock split since its BSE/NSE listing. The latest announcement for Caplin Point Labs stock split was on Oct 19, 2016 at a ratio of 10:2.
Caplin Point Labs reported ₹643.91 Cr. in revenue, ₹176.91 Cr. in net profit, and ₹247.03 Cr. in EBITD as of Aug 12, 2026 for Q1 FY26-27.
According to the predictions of 2 analysts, the share price prediction for Caplin Point Labs is ₹2,765 with an upside of 19%.
The PE ratio of Caplin Point Labs is 26.57 as of Oct 30, 2026.
The PB ratio of Caplin Point Labs is 4.69 as of Oct 30, 2026.
You can view the latest analyst reports on the Caplin Point Labs reports dashboard. Either click on the Reports tab on this page's sub-header or click here to be directed to the dashboard.
You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.
Ask AI
×